Tapentadol Hydrochloride tablets are indicated for the management of moderate to severe acute pain in adult patients aged 18 years and above.

Tapentadol is a centrally acting synthetic analgesic with a dual mechanism of action. It primarily functions as a selective mu-opioid receptor (MOR) agonist, showing significantly higher affinity for MOR compared to delta and kappa opioid receptors. In addition, tapentadol inhibits the reuptake of noradrenaline, leading to increased levels of noradrenaline and activation of alpha-2 receptors, which contributes to its analgesic effect. Although it has a weak inhibitory effect on serotonin reuptake, this mechanism is not considered clinically significant for pain relief.

As with many centrally-acting analgesic medications, the dosing regimen should be individualized according to the severity of pain being treated, the previous experience with similar drugs and the ability to monitor the patient.

The dose is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 50 mg, 75 mg, or 100 mg every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.

Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.

The risk of serotonin syndrome may increase when Tapentadol is used with other drugs that enhance monoaminergic neurotransmission, such as TCAs, triptans, SSRIs, and serotonin-norepinephrine reuptake inhibitors (SNRIs). Its sedative effects may be enhanced when combined with benzodiazepines, barbiturates, antipsychotics, H1-antihistamines, and other opioids. There may be an increased risk of dependence when used with mixed μ-opioid agonist/antagonists (e.g., nalbuphine, pentazocine) or partial μ-opioid agonists (e.g., buprenorphine). Systemic exposure of Tapentadol may increase when used with strong inhibitors of UGT1A6, UGT1A9, and UGT2B7 enzymes, while its effectiveness may decrease when used with strong enzyme inducers such as rifampicin or phenobarbital.

Tapentadol is contraindicated in patients with impaired pulmonary function. It should not be used in patients with acute or severe bronchial asthma or hypercapnia in unmonitored settings or where resuscitation equipment is not available. It is also contraindicated in patients with known or suspected paralytic ileus.

Possible adverse effects include increased or decreased heart rate, visual disturbances, abdominal discomfort, delayed gastric emptying, irritability, edema, withdrawal symptoms, hypersensitivity reactions, involuntary muscle contractions, heaviness sensation, reduced sensation, tingling, attention disturbances, sedation, speech difficulty, memory impairment, lack of coordination, dizziness, fainting, seizures, urticaria, and decreased blood pressure.

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Tapentadol should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Newborns of mothers taking Tapentadol should be monitored for respiratory depression.

Tapentadol should be used cautiously in patients with respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), hypoxia, or hypercapnia. Extra caution is needed in patients with sleep apnea, myxedema, kyphoscoliosis, or central nervous system depression. Concomitant use with other CNS depressants (including alcohol, sedatives, tranquilizers, general anesthetics, and opioids) may lead to additive CNS depression.

Pediatric Use: Safety and effectiveness in patients under 18 years have not been established.

Elderly Use: Elderly patients with normal renal and hepatic function may use standard adult doses, but treatment should be initiated at the lower end of the dosing range.

Renal Impairment: Safety and effectiveness in severe renal impairment have not been established.

Hepatic Impairment: Use cautiously in moderate hepatic impairment; not studied in severe hepatic impairment.

Opioid analgesic

Store in a cool, dry place, protected from light and moisture. Keep out of reach of children.